Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone510-871-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.19 million
Profitability
Miscellaneous
Employees113
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions
What is Gritstone Oncology's stock symbol?
Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."
How were Gritstone Oncology's earnings last quarter?
Gritstone Oncology Inc (NASDAQ:GRTS) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.03. The business earned $1.35 million during the quarter, compared to the consensus estimate of $1.20 million. View Gritstone Oncology's Earnings History.
When is Gritstone Oncology's next earnings date?
What price target have analysts set for GRTS?
7 Wall Street analysts have issued 1-year target prices for Gritstone Oncology's stock. Their forecasts range from $17.00 to $31.00. On average, they expect Gritstone Oncology's share price to reach $22.20 in the next year. This suggests a possible upside of 98.6% from the stock's current price. View Analyst Price Targets for Gritstone Oncology.
What is the consensus analysts' recommendation for Gritstone Oncology?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gritstone Oncology.
What are Wall Street analysts saying about Gritstone Oncology stock?
Here are some recent quotes from research analysts about Gritstone Oncology stock:
- 1. According to Zacks Investment Research, "Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patients tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients TSNA to drive the patients immune system to attack and destroy tumors. " (5/14/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of GRTS and our 12-month price target of $17.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected GRANITE-001 and SLATE-001 revenues through 2030, assuming a 12.5% discount rate and 3% terminal growth rate." (4/1/2019)
Has Gritstone Oncology been receiving favorable news coverage?
Press coverage about GRTS stock has trended positive on Sunday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Gritstone Oncology earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Gritstone Oncology's key competitors?
Some companies that are related to Gritstone Oncology include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), Autolus Therapeutics (AUTL), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), MeiraGTx (MGTX) and Cellectis (CLLS).
What other stocks do shareholders of Gritstone Oncology own?
Who are Gritstone Oncology's key executives?
Gritstone Oncology's management team includes the folowing people:
- Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)
- Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)
- Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)
- Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)
- Dr. Roman Yelensky, Exec. VP & CTO (Age 40)
When did Gritstone Oncology IPO?
(GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.
When did the company's lock-up period expire?
Gritstone Oncology's lock-up period expired on Wednesday, March 27th. Gritstone Oncology had issued 6,666,667 shares in its IPO on September 28th. The total size of the offering was $100,000,005 based on an initial share price of $15.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Gritstone Oncology's major shareholders?
Gritstone Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.00%), BlackRock Inc. (1.45%), Victory Capital Management Inc. (0.93%), JPMorgan Chase & Co. (0.41%), Marshall Wace LLP (0.37%) and Riverhead Capital Management LLC (0.16%). View Institutional Ownership Trends for Gritstone Oncology.
Which major investors are selling Gritstone Oncology stock?
GRTS stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, JPMorgan Chase & Co., California State Teachers Retirement System and Riverhead Capital Management LLC. View Insider Buying and Selling for Gritstone Oncology.
Which major investors are buying Gritstone Oncology stock?
GRTS stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Marshall Wace LLP, BlackRock Inc., FMR LLC, Marshall Wace North America L.P. and New York State Common Retirement Fund. View Insider Buying and Selling for Gritstone Oncology.
How do I buy shares of Gritstone Oncology?
Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gritstone Oncology's stock price today?
One share of GRTS stock can currently be purchased for approximately $11.18.
How big of a company is Gritstone Oncology?
Gritstone Oncology has a market capitalization of $399.35 million and generates $1.19 million in revenue each year. The company earns $-64,780,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.
What is Gritstone Oncology's official website?
How can I contact Gritstone Oncology?
Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]
MarketBeat Community Rating for Gritstone Oncology (NASDAQ GRTS)
MarketBeat's community ratings are surveys of what our community members think about Gritstone Oncology and other stocks. Vote "Outperform" if you believe GRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
